作为潜在的生物标志物和治疗点在炎症性关节炎症中,PIM基因酶
Elisa Assirelli1, Jacopo Ciaffi1, Valentina Scorcu1
1Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
International journal of molecular sciences
|March 28, 2024
概括
在炎症性关节炎中,PIM激酶被放松调节,与健康个体相比,在患有类风湿性关节炎,牛皮性关节炎和轴性脊椎关节炎的患者中观察到改变的PIM-1和PIM-3蛋白水平. 治疗没有改变这些PIM激酶水平.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 类风湿病学 类风湿病学
背景情况:
- 皮姆基因酶 (PIM-1, -2, -3) 调节关键细胞过程,如生存和繁殖.
- 皮姆基因酶与类风湿性关节炎的发病有关.
- 它们在牛皮关节炎和轴性脊椎关节炎中的作用仍然未被探索.
研究的目的:
- 研究炎症性关节炎 (RA,PsA,axSpA) 中的PIM激酶表达.
- 为了将PIM激酶水平与促炎性细胞因子相关联.
- 评估生物DMARD或JAK抑制剂治疗后PIM激酶表达的变化.
主要方法:
- 对PIM-1, -2,和-3.3的基因和蛋白质表达分析.
- 样本包括外周血液单核细胞和来自RA,PsA,axSpA患者的血清,以及健康对照.
- 表达水平在各组之间和治疗6个月后进行了比较.
主要成果:
- 在所有样本中,PIM-1, -2,和 -3 激酶都在基因和蛋白质水平上表达.
- 蛋白质PIM-1是最高的,PIM-3是最低的.
- 与对照组相比,患者的PIM-1蛋白减少,PIM-3蛋白增加,疾病类型之间没有差异.
- 治疗没有改变PIM激酶水平.
结论:
- 初步数据表明,在炎症性关节炎症中,PIM途径的放松调节.
- 需要进一步的研究来阐明PIM激酶在这些条件中的特定作用.
- 在炎症性关节炎中,PIM激酶是潜在的治疗点.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
MAPK Signaling Cascades
5.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
173
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
173
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Phosphoinositides and PIPs
8.5K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.5K


